Project Grant R01AI179632

Award Date 6/13/24

Completion Date 4/30/29

Dollars Obligated $1.8M

Federal Agency

National Institute of Allergy and Infectious Diseases

Awardee

University Of Tennessee (X1M1PN3KG3E7)

Federal Grant Program

93.855

Assistance Type

Project Grant

Place of Performance

Memphis, TN 38103, USA

Similar Awards

Project Grant R01AI181792
This $1,032,868 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports a research program to study the molecular mechanisms regulating neutrophil proinflammatory and adhesive activities in sepsis. The key objectives are to: Determine the molecular basis of neutrophil A20 signaling in regulating neutrophil proinflammatory function under septic conditions. Utilize two-photon intravital microscopy to...
Project Grant R35GM160530
This federal Project Grant award of $462,981, provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), aims to advance the understanding of sepsis biology and care. The overarching goal is to gain a holistic understanding of the complex genetic, clinical, behavioral, and social factors that contribute to sepsis risk and outcomes. The research program will leverage large, diverse electronic health...
Project Grant R21AI184402
The University of Rochester received a $462,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research grant program (CFDA 93.855), to investigate how the human microbiome differentially primes the immune system and influences susceptibility to sepsis. The research will examine how neutrophils in healthy human blood are "trained" by the microbiome, leading to altered responses to inflammatory...
Project Grant R35GM156920
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), aims to unravel the relationships between gut microbial communities, blood microbial signatures, and immune responses in sepsis patients. The $403,750.00 award, granted on May 1, 2025, will support a prospective longitudinal cohort study at Duke University to integrate gut microbial profiling, metabolomics, intestinal permeability...
Project Grant R21AI188227
This $473,937 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) is funding research to develop a novel liquid biopsy approach for early detection of sepsis-induced organ damage. The project aims to detect tissue-derived circulating rare cells (TCRCs) in patient blood samples as a biomarker for diagnosing and monitoring sepsis, COVID-19, and other systemic infectious...
Project Grant R35GM160273
The Project Grant titled "NOVEL BURN SEPSIS PROGNOSTIC STRATEGIES: DECIPHERING EARLY IMMUNE PROGENITOR SHIFTS IN BURN SEPSIS DEVELOPMENT AND MODULATION OF HOST BURN RESPONSE THROUGH ANGIOPOIETIN-TIE SIGNALING" was awarded by the National Institute of General Medical Sciences (CFDA 93.859 Biomedical Research and Research Training program) to Loyola University of Chicago's Health Sciences Campus. The $423,500 grant, awarded on August 5, 2025, aims to address two critical challenges in...
Project Grant R01AI194573
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research CFDA program (93.855), aims to define the molecular and cellular mechanisms of non-canonical inflammasome responses to lipopolysaccharide (LPS) in mice and humans. The $3,204,624 award to the University of Pennsylvania will support research to investigate how bacterial pathogens can evade innate immune sensing by Toll-like receptor 4 (TLR4) and...
Project Grant R21AI191116
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $430,375 to Emory University to conduct research on a novel inter-membrane lipid signaling mechanism that enables gram-negative bacteria like E. coli and Pseudomonas to maintain the integrity of their outer membrane and resist antibiotic treatments. The research aims to uncover how bacteria can sense and respond to...
Project Grant R35GM156197
This federal Project Grant award of $410,000 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports research to investigate the role of pathological autoantibodies in immune suppression during sepsis. The project aims to determine the prevalence of autoantibodies, such as anti-cytokine autoantibodies and anti-Fas autoantibodies, in sepsis patients, and to elucidate the mechanisms by which these...
Project Grant F30GM153101
The National Institute of General Medical Sciences (NIGMS) awarded a $108,512 project grant under the Biomedical Research and Research Training program (CFDA 93.859) to The Research Foundation for The State University of New York (RF SUNY) on January 15, 2025. This grant supports research aimed at "Targeting Both Hyperinflammation and Pyroptosis via Nanotherapeutics to Improve Outcomes in Gram-Negative Sepsis". The project focuses on developing an immune-modulating nanotherapy that can...

THE MOLECULAR MECHANISM OF SIGLEC-E IN BACTERIAL CLEARANCE - SEPSIS IS A SYSTEMIC INFLAMMATORY RESPONSE SYNDROME INITIATED BY INFECTION. MOST CASES OF SEPTIC SHOCK ARE CAUSED BY GRAM-NEGATIVE BACTERIA, INCLUDING ESCHERICHIA COLI (E. COLI), WHICH REMAINS ONE OF THE MOST COMMON PATHOGENS LEADING TO SEPSIS. UNDERSTANDING THE MECHANISMS BY WHICH THE MAMMALIAN IMMUNE SYSTEM DIFFERENTIALLY RESPONDS TO INFECTION BY GRAM-NEGATIVE AND GRAM-POSITIVE BACTERIA WILL PLACE US IN A BETTER POSITION TO TREAT OR PREVENT SEPSIS. MEMBERS OF THE SIALIC ACID-BINDING IMMUNOGLOBULIN-LIKE LECTIN FAMILY (SIGLECS) ARE CELL SURFACE RECEPTORS THAT NEGATIVELY REGULATE THE RESPONSE TO INFECTION BY BINDING OR TAKING UP SIALYLATED PATHOGENS; HOWEVER, MOST PATHOGENS ARE NOT SIALYLATED. WE PREVIOUSLY PUBLISHED A STUDY IN WHICH WE USED NONSIALYLATED BACTERIA TO SHOW THAT SIGLEC-E KNOCKOUT (SIGLECE-/-) MICE EXHIBITED HIGHER MORTALITY THAN WILD-TYPE (WT) MICE FOLLOWING INFECTION BY GRAM-NEGATIVE BUT NOT GRAM-POSITIVE BACTERIA. BETTER SURVIVAL IN WT MICE DEPENDED ON MORE EFFICIENT CLEARANCE OF GRAM-NEGATIVE THAN GRAM-POSITIVE BACTERIA. MOREOVER, INFECTION WITH GRAM-NEGATIVE E. COLI STRAINS 25922 AND DH5A INDUCED THE EXPRESSION OF SIGLEC-E, WHICH PROMOTED PRODUCTION OF REACTIVE OXYGEN SPECIES (ROS). IN CONTRAST, INFECTION WITH GRAM-POSITIVE BACTERIA STAPHYLOCOCCUS AUREUS OR LISTERIA MONOCYTOGENES REDUCED EXPRESSION OF SIGLEC-E, WHICH INHIBITED PRODUCTION OF ROS. BASED ON THESE FINDINGS, WE DESIGNED THIS PROJECT TO: 1) ELUCIDATE THE MOLECULAR MECHANISMS OF SIGLEC-E IN BACTERIAL CLEARANCE; 2) DISSECT THE MOLECULAR MECHANISMS UNDERLYING DIFFERENTIAL REGULATION OF INNATE IMMUNE RESPONSE DURING INFECTION WITH GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA BY CONTROLLING SIGLEC-E; 3) EVALUATE SIGLEC-E AS A THERAPEUTIC TARGET FOR THE TREATMENT OF BACTERIAL SEPSIS BY USING CLP. THESE STUDIES WILL NOT ONLY REVEAL THE MOLECULAR MECHANISMS OF THE NOVEL ROLE OF SIGLEC-E IN BACTERIAL CLEARANCE BUT ALSO PROVIDE NOVEL APPROACHES TOWARD TREATMENT OF BACTERIAL INDUCED-SEPSIS.

Posted 6/13/24

Mod #	Federal Obligation	Date
Not listed	$462.0k	4/10/25
Not listed	$46.2k	9/3/24
Not listed	$46.2k	9/3/24
Not listed	$415.8k	6/13/24
Not listed	$415.8k	6/13/24